Cargando…

Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene

The positive link between osteoporosis and hypercholesterolemia has been documented, and bone resorption inhibitors, such as nitrogen-containing bisphosphonates (N-BP) and selective estrogen receptor modulators (SERMs), are known to reduce serum cholesterol levels. However, the relationship between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohta, Hiroaki, Uemura, Yukari, Sone, Teruki, Tanaka, Shiro, Soen, Satoshi, Mori, Satoshi, Hagino, Hiroshi, Fukunaga, Masao, Nakamura, Toshitaka, Orimo, Hajime, Shiraki, Masataka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025188/ https://www.ncbi.nlm.nih.gov/pubmed/36707436 http://dx.doi.org/10.1007/s00223-023-01060-9

Ejemplares similares

Three years of treatment with minodronate in patients with postmenopausal osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2011)

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
por: Okazaki, R., et al.
Publicado: (2011)

Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary
por: Orimo, Hajime, et al.
Publicado: (2012)

Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial‐05 (JOINT‐05)
por: Tanaka, Shiro, et al.
Publicado: (2022)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
por: Mori, Satoshi, et al.
Publicado: (2022)

The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis
por: Hasegawa, Eriko, et al.
Publicado: (2018)

Minodronate for the treatment of osteoporosis
por: Ohishi, Tsuyoshi, et al.
Publicado: (2018)

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study
por: Matsumoto, T., et al.
Publicado: (2008)

Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2012)

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
por: Sugimoto, Toshitsugu, et al.
Publicado: (2017)

A review of minodronic acid hydrate for the treatment of osteoporosis
por: Tanishima, Shinji, et al.
Publicado: (2013)

Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis
por: Liu, Qingshan, et al.
Publicado: (2020)

Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study
por: Matsumoto, Toshio, et al.
Publicado: (2022)

Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate
por: Kamimura, Mikio, et al.
Publicado: (2016)

A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05
por: Hagino, H., et al.
Publicado: (2021)

The effects of minodronate and activated vitamin D on bone mineral density and muscle mass in postmenopausal women with osteoporosis
por: Fujimoto, Kazuki, et al.
Publicado: (2018)

Utility of monthly minodronate for osteoporosis after gastrectomy: Prospective multicenter randomized controlled trials
por: Hirota, Masashi, et al.
Publicado: (2021)

Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis
por: Lu, Hsing-Fang, et al.
Publicado: (2020)

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis
por: Sone, Teruki, et al.
Publicado: (2017)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
por: Nakamura, T., et al.
Publicado: (2016)

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
por: Kobayashi, Masaki, et al.
Publicado: (2020)

Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol
por: Nakamura, Toshitaka, et al.
Publicado: (2013)

Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
por: Nakamura, Toshitaka, et al.
Publicado: (2014)

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study
por: Suzuki, Takako, et al.
Publicado: (2019)

Effect of aerobic exercise and raloxifene combination therapy on senile osteoporosis
por: Zhao, Chengjin, et al.
Publicado: (2016)

Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women
por: Um, Mi Jung, et al.
Publicado: (2017)

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
por: Kim, Yeesuk, et al.
Publicado: (2020)

Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
por: Shiraki, Masataka, et al.
Publicado: (2021)

Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment
por: Nagai, Noriaki, et al.
Publicado: (2018)

Influence on the bone mineral density and bone metabolism marker after the interruption and reinitiation of monthly minodronate therapy in postmenopausal women with osteoporosis
por: Okimoto, Nobukazu, et al.
Publicado: (2018)

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
por: Tanaka, Mizue, et al.
Publicado: (2017)

Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats
por: Lama, Adriano, et al.
Publicado: (2017)

Drug-induced hypersensitivity syndrome caused by minodronic acid hydrate
por: Muto, Yutaka, et al.
Publicado: (2021)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
por: Fujiwara, Saeko, et al.
Publicado: (2014)

Investigation of the treatment potential of Raloxifene-loaded polymeric nanoparticles in osteoporosis: In-vitro and in-vivo analyses
por: Guo, Zhonghua, et al.
Publicado: (2023)

Minodronate treatment improves low bone mass and reduces progressive thoracic scoliosis in a mouse model of adolescent idiopathic scoliosis
por: Tanabe, Hironori, et al.
Publicado: (2018)

Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
por: Vogel, Victor G
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_gu40kaora77md22phoamjdb8ra